Key Investor Signals
€1.25M non-dilutive EXIST research funding
RevoBITs received €1.25M in December 2025 through EXIST Research Transfer, the German federal programme supporting technology transfer from research institutions.
Piloting BYTE1 with two university hospitals
The team is piloting its byte 1 system with the university hospitals in Würzburg and FAU Erlangen, giving it early users inside academic clinical research groups.
Partnered on German–Australian brain-model research
RevoBITs is a partner in a German–Australian research collaboration building brain tissue models, applying its printing hardware to neural constructs.
Other Positive Signals
- Secured €36,000 through Bavaria's Start?Zuschuss! programme in October 2026, among 11 teams selected in its 22nd round.
- Won the 2023 m4 Award, a Bavarian public prize for biomedical startup projects.
- The BYTE1 prototype was used in published optical bioink-characterization experiments in 2024.
Team
Stefan Schrüfer
CEO and Co-founder
- Completed a PhD in polymer materials at FAU Erlangen-Nürnberg, working on printable material systems.
- Leads RevoBITs' commercial strategy and its public funding and transfer programmes.
Ruben Gerrit Scheuring
CTO and Co-founder
- Completed a PhD in functional materials at the University of Würzburg, focused on tissue engineering.
- Leads development of the multi-material printhead and inline sensing technology.
Alexander Björk
CIO and Co-founder
- Holds a B.Sc. in aerospace engineering and an M.Sc. in computer science.
- Leads software and control systems for the byte 1 platform.
Janik Altenhöfer
COO and Co-founder
- Worked in product management for electronics before co-founding RevoBITs.
- Runs operations, manufacturing and customer delivery.
Product
byte 1 is RevoBITs' bioprinting system, built around a multi-material printhead designed for research groups producing human tissue models.
Multi-material printhead
The printhead can handle up to 100 material compositions in a single run, allowing gradients and combinations that single-material systems cannot produce.
Two independent temperature zones
Separate zones operating from 4 to 50°C let sensitive bioinks and cell suspensions be held at different temperatures during the same print.
Inline sensing during printing
Integrated sensing monitors the print as it happens, giving researchers process data rather than only an end-point inspection.
Market Overview
Most drug candidates fail in clinical development after passing preclinical testing, in part because conventional cell culture does not reproduce the structure of human tissue. Regulators and funders are increasingly open to human-relevant models, and the FDA has signalled support for reducing reliance on animal testing.
Bioprinting hardware sits upstream of that shift. Academic and industrial groups building tissue models need instruments that can place several materials and cell types precisely, which is where RevoBITs positions its system.
Estimated global market value for 3D bioprinting technologies.
Estimated annual research and development spending across the European pharmaceutical industry.
Share of drug candidates entering clinical development that do not reach approval.
Reported compound annual growth rate for organ-on-chip and related human model systems.
Comparable Outcomes
MatTek and Visikol
MatTek produced reconstructed human tissue models and Visikol provided advanced imaging and analysis services for preclinical research. Sartorius acquired both businesses for $80M in July 2025.
Scienion
Scienion developed precision dispensing instruments used in diagnostics manufacturing and life science research. CELLINK acquired Scienion for €80M in September 2020.
Interested in More Startups Like RevoBITs?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.